Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Randomized Phase Ii Trial Of Weekly Docetaxel, Estramustine And Prednisone Versus Docetaxel And Prednisone In Patient With Hormone-Resistant Prostate Cancer
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
This PHASE2 trial investigates Hormone Resistant Prostate Cancer and Metastatic Prostate Cancer and is currently completed. Cliniques universitaires Saint-Luc- Université Catholique de Louvain leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baudour, Belgium , Bouge, Belgium , Boussu, Belgium , Brasschaat, Belgium , Brussels, Belgium , Charleroi, Belgium , Eupen, Belgium , Gilly, Belgium , Gosselies, Belgium , La Louvière, Belgium and 7 more locations